Skip to main content

Table 2 Medical oncologist summarized responses

From: Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events

001 Variable based on the type of treatment. Surgery, radiation, chemotherapy, targeted therapies. Overall, the most common toxicity is fatigue or pain.
002 There are 4 main adverse events with sorafenib and a variety of others that are fairly uncommon. The 4 main symptoms are fatigue, skin toxicity (hand-foot syndrome or rash), diarrhea, and arterial hypertension.
003 With sorafenib, rash is the most common. We haven’t really seen cumulative toxicity with immune therapies, though, because patients usually haven’t been on treatment more than 3 months.
004 Post–transcatheter arterial chemoembolization (TACE) syndrome can occur, which includes fever, chills, abdominal pain and would last about 3 to 7 days. Sorafenib has significant skin toxicity—hand-foot syndrome and diarrhea, which can be very severe. Hypertension is another side effect, although it is not symptomatic. Skin toxicity is very typical with sorafenib and is definitely not related to the disease.
005 Patients will have pain, fatigue, and nausea after local-regional therapy. Patients who receive sorafenib experience fatigue, loss of appetite, diarrhea (about 10% have significant diarrhea), skin toxicities, rashes, and some hypertension.